TGEN

Targeted Genetics Reports Positive Results From Phase 1/2 Clinical Study For Leber's Congenital Amaurosis - Quick Facts - 04/27 - 05:22 PM ET

Targeted Genetics Announces Encouraging Results From Phase 1/2 Clinical Study For Leber's Congenital Amaurosis - 04/27 - 05:16 PM ET

Targeted Genetics Received Staff Deficiency Letter From Nasdaq - Quick Facts - 04/25 - 08:09 PM ET

Targeted Genetics Gets Nasdaq Deficiency Letter For Non-Compliance With Minimum Bid Price Requirement - 04/25 - 08:03 PM ET

Targeted Genetics Advances In Pre-Market On Publication Of Preclinical Data - 04/09 - 08:56 AM ET

Targeted Genetics Corp. (TGEN) Corporate Event Announcement Notice - 03/26 - 09:10 PM ET

Targeted Genetics Corp. (TGEN) Corporate Event Announcement Notice - 03/25 - 09:08 PM ET

Targeted Genetics Q4 & FY07 Earnings Conference Call At 10:30 AM - 03/25 - 09:54 AM ET

Targeted Genetics To Present At Invest Northwest Investor And CEO Forum 2008; Webcast At 11:40 AM - 03/18 - 10:46 AM ET

Targeted Genetics Corp. (TGEN) Corporate Event Announcement Notice - 03/12 - 09:10 PM ET

Targeted Genetics Corp. (TGEN) Corporate Event Announcement Notice - 03/11 - 09:18 PM ET

Recombinant DNA Advisory Committee Says Death In Targeted Genetics' Phase I/II Trial Of TgAAC94 Was Due To Opportunistic Infection, Disseminated Histoplasmosis - 12/03 - 05:24 PM ET

Targeted Genetics Reports On Recombinant DNA Advisory Committee Assessment Of Phase I/II Trial Of TgAAC94 For Inflammatory Arthritis - Quick Facts - 12/03 - 04:40 PM ET

Targeted Genetics Announces Recombinant DNA Advisory Committee Assessment Of Its Phase I/II Trial Of TgAAC94 For Inflammatory Arthritis - 12/03 - 04:32 PM ET

Targeted Genetics Up In Pre-Market Trading On FDA News - 11/26 - 09:16 AM ET

Targeted Genetics Says FDA Removed Hold On Phase I/II Clinical Trial Of TgACC94 For Inflammatory Arthritis - Update - 11/26 - 08:41 AM ET

Targeted Genetics Says FDA Has Removed Hold On Phase I/II Clinical Trial Of TgAAC94 For Inflammatory Arthritis - Quick Facts - 11/26 - 07:41 AM ET

Targeted Genetics Says FDA Has Removed Hold On Phase I/II Clinical Trial Of TgAAC94 For Inflammatory Arthritis - 11/26 - 07:34 AM ET

Targeted Genetics Unveils Positive Interim Phase I/II Results For TgAAC94 In Inflammatory Arthritis - Quick Facts - 11/10 - 08:10 AM ET

Targeted Genetics Announces Positive Interim Phase I/II Results - 11/10 - 08:06 AM ET

Page 1 of 1     1     Previous  |  Next

<< Back to Stock Index